Increased rates of respiratory disease in schizophrenia: A systematic review and meta-analysis including 619,214 individuals with schizophrenia and 52,159,551 controls.


Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
11 2021
Historique:
received: 10 10 2020
revised: 10 08 2021
accepted: 22 08 2021
pubmed: 15 9 2021
medline: 26 3 2022
entrez: 14 9 2021
Statut: ppublish

Résumé

Despite respiratory disease being a major cause of excess mortality in people with schizophrenia, the prevalence of respiratory conditions in this population is poorly defined. A systematic review and meta-analysis were conducted to establish the prevalence and association of respiratory diseases in people with schizophrenia. Major electronic databases were searched from inception to 27 April 2020 for articles reporting respiratory disease (asthma, chronic obstructive pulmonary disease [COPD], pneumonia, and tuberculosis) in people with schizophrenia and, where possible, a control group. A random-effects meta-analysis was conducted. The study was registered with PROSPERO (CRD42018115137). Of 1569 citations, 21 studies consisting of 619,214 individuals with schizophrenia and 52,159,551 controls were included in the meta-analysis. Compared to the general population, people with schizophrenia had significantly higher rates of COPD (odds ratio [OR]: 1.82, 95% CI: 1.28-2.57), asthma (OR: 1.70, 95% CI: 1.02-2.83), and pneumonia (OR: 2.62, 95% CI: 1.10-6.23). In people with schizophrenia, the prevalence of COPD was 7.7% (95% CI: 4.0-14.4), asthma 7.5% (95% CI: 4.9-11.3), pneumonia 10.3% (95% CI 5.4-18.6), and tuberculosis 0.3% (95% CI 0.1 -0.8). After adjusting for publication bias, the prevalence of COPD increased to 19.9% (95% CI: 9.6-36.7). All respiratory diseases examined were significantly more prevalent in people with schizophrenia compared with the general population. Future studies should focus on improving the prevention and management of respiratory disease in this group to reduce associated excess mortality.

Identifiants

pubmed: 34521040
pii: S0920-9964(21)00347-9
doi: 10.1016/j.schres.2021.08.022
pii:
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

131-140

Subventions

Organisme : Department of Health
ID : ICA-CL-2017-03-001
Pays : United Kingdom

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Shuichi Suetani (S)

Physical and Mental Health Stream, Queensland Centre for Mental Health Research, Wacol, QLD 4076, Australia; Queensland Brain Institute, The University of Queensland, St Lucia, QLD 4072, Australia; Metro South Addiction and Mental Health Services, Woolloongabba, QLD 4102, Australia; School of Medicine, Griffith University, Nathan, QLD 4111, Australia; Institute for Urban Indigenous Health, Windsor, QLD 4030, Australia.

Faraz Honarparvar (F)

School of Medicine, The University of Queensland, Herston, QLD 4102, Australia.

Dan Siskind (D)

Physical and Mental Health Stream, Queensland Centre for Mental Health Research, Wacol, QLD 4076, Australia; Metro South Addiction and Mental Health Services, Woolloongabba, QLD 4102, Australia; School of Medicine, The University of Queensland, Herston, QLD 4102, Australia.

Guy Hindley (G)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom; NORMENT, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, 0407 Oslo, Norway.

Nicola Veronese (N)

Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, 90100 Palermo, Italy.

Davy Vancampfort (D)

KU Leuven Department of Rehabilitation Sciences, Leuven, Belgium; KU Leuven, University Psychiatric Center KU Leuven, Leuven-Kortenberg, Belgium.

Lauren Allen (L)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom.

Marco Solmi (M)

Department of Neuroscience, University of Padova, Padova, Italy; Padua Neuroscience Center, University of Padova, Padova, Italy.

John Lally (J)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom; Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Psychiatry, Mater Misericordiae University Hospital, Dublin, Ireland.

Fiona Gaughran (F)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom; South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ, United Kingdom.

Brendon Stubbs (B)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom; South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ, United Kingdom; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, Box SE5 8AF, United Kingdom. Electronic address: brendon.stubbs@kcl.ac.uk.

Toby Pillinger (T)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom; South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH